Found: 133
Select item for more details and to access through your institution.
Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 93, n. 3, p. 253, doi. 10.1007/s00280-023-04629-1
- By:
- Publication type:
- Article
5‐HT1A Receptor Agonist, SUVN‐N9503012 for the Treatment of Dementia and Associated Neuropsychiatric Disorders.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074640
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer's Type: Preliminary Efficacy and Phase‐3 Study Design.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074068
- By:
- Publication type:
- Article
SUVN‐I6107: A True Positive Allosteric Modulator (PAM) at Muscarinic M1 Receptors for the Treatment of Cognitive Disorders.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074091
- By:
- Publication type:
- Article
Role of Onset of Diabetes on Development of Cognitive Impairment in Rats.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.075193
- By:
- Publication type:
- Article
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 2, p. 309, doi. 10.3390/biom13020309
- By:
- Publication type:
- Article
Usmarapride Oxalate (SUVN‐D4010): A Serotonin‐4 Receptor Partial Agonist for the Treatment of Cognitive Disorders.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.062167
- By:
- Publication type:
- Article
Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN‐502): A Post‐hoc Analysis of a Phase‐2 Randomized Placebo‐Controlled Study.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.062688
- By:
- Publication type:
- Article
Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer's Disease: A Post Hoc Analysis.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.062695
- By:
- Publication type:
- Article
SUVN‐I7016031: A Novel M<sub>1</sub>‐receptor Positive Allosteric Modulator (M<sub>1</sub>‐PAM) for the treatment of Parkinson's Disease Associated Dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 3, p. 1, doi. 10.1002/alz.062698
- By:
- Publication type:
- Article
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study.
- Published in:
- Neurology & Therapy, 2022, v. 11, n. 4, p. 1583, doi. 10.1007/s40120-022-00390-4
- By:
- Publication type:
- Article
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 9, p. 747, doi. 10.1007/s40261-022-01189-9
- By:
- Publication type:
- Article
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
- Published in:
- Psychopharmacology, 2022, v. 239, n. 7, p. 2215, doi. 10.1007/s00213-022-06108-6
- By:
- Publication type:
- Article
1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H<sub>3</sub> Receptor Inverse Agonist with Efficacy in Animal Models of Cognition
- Published in:
- ChemMedChem, 2022, v. 17, n. 3, p. 1, doi. 10.1002/cmdc.202100583
- By:
- Publication type:
- Article
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, v. 8, n. 1, p. 1, doi. 10.1002/trc2.12307
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer's dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051571
- By:
- Publication type:
- Article
SUVN‐I6107: Efficacy and safety assessments of a true muscarinic M1‐positive allosteric modulator for the treatment of dementia.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051652
- By:
- Publication type:
- Article
Metformin, a calorie restriction mimetic for the treatment of Alzheimer's disease: A preclinical investigation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, n. 3, p. 1, doi. 10.1002/alz.051635
- By:
- Publication type:
- Article
SUVN‐D4010: A serotonin‐4 receptor partial agonist for the treatment of cognitive disorders.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, n. 3, p. 1, doi. 10.1002/alz.051644
- By:
- Publication type:
- Article
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders.
- Published in:
- Journal of Psychopharmacology, 2021, v. 35, n. 6, p. 713, doi. 10.1177/0269881120986418
- By:
- Publication type:
- Article
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
- Published in:
- Psychopharmacology, 2021, v. 238, n. 6, p. 1495, doi. 10.1007/s00213-021-05779-x
- By:
- Publication type:
- Article
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 5, p. 469, doi. 10.1007/s40261-021-01027-4
- By:
- Publication type:
- Article
SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits: Biomarkers (non‐neuroimaging)/Prognostic utility.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039288
- By:
- Publication type:
- Article
Masupirdine in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Subgroup analyses of memantine regimen, plasma concentrations and duration of treatment: Human/Human trials: Other.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039254
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patient's age on efficacy endpoints: Human/Human trials: Cognitive enhancement.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039283
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimer's disease: Human/Human trials: Other behavioral symptoms.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039303
- By:
- Publication type:
- Article
Masupirdine (SUVN‐502): A pure 5‐HT<sub>6</sub> receptor antagonist ameliorates aggression‐like behavior in animal models: Development of new models and analysis methods/behavioral models.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.039312
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
- Published in:
- Clinical Drug Investigation, 2020, v. 40, n. 7, p. 603, doi. 10.1007/s40261-020-00920-8
- By:
- Publication type:
- Article
P4‐660: TRIPLE THERAPY WITH MASUPIRDINE (SUVN‐502), A 5‐HT<sub>6</sub> ANTAGONIST, DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER'S DISEASE: BASELINE PATIENT CHARACTERISTICS IN A PHASE‐2A STUDY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1584, doi. 10.1016/j.jalz.2019.09.026
- By:
- Publication type:
- Article
P3‐434: SUVN‐502: A PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST ATTENUATES MEMORY DEFICITS INDUCED BY DIVERSE CHALLENGES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1127, doi. 10.1016/j.jalz.2019.06.3468
- By:
- Publication type:
- Article
P3‐193: SUVN‐502: IN‐VITRO PHARMACOLOGICAL PROFILE OF A PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1004, doi. 10.1016/j.jalz.2019.06.3222
- By:
- Publication type:
- Article
P3‐042: SUVN‐502: A PURE 5‐HT<sub>6</sub> ANTAGONIST POTENTIATES THE EFFECTS OF DONEPEZIL OR MEMANTINE IN ANIMAL MODELS OF COGNITION, NEUROCHEMISTRY AND ELECTROPHYSIOLOGY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P942, doi. 10.1016/j.jalz.2019.06.3068
- By:
- Publication type:
- Article
P2‐031: SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN‐502, A POTENT AND PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P583, doi. 10.1016/j.jalz.2019.06.1253
- By:
- Publication type:
- Article
P2‐083: SUVN‐502: A PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST AMELIORATES SENILE DEMENTIA IN ANIMAL MODELS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P604, doi. 10.1016/j.jalz.2019.06.2490
- By:
- Publication type:
- Article
P1‐089: SUVN‐502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION): FIRST‐IN‐CLASS AND A PROMISING NEW APPROACH FOR THE SYMPTOMATIC TREATMENT OF ALZHEIMER'S DISEASE DEMENTIA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P269, doi. 10.1016/j.jalz.2019.06.644
- By:
- Publication type:
- Article
P3‐455: SUVN‐M8036, A SEROTONERGIC AND DOPAMINERGIC MODULATOR, ALLEVIATES PSYCHOSIS AND DEPRESSION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1292, doi. 10.1016/j.jalz.2018.06.1819
- By:
- Publication type:
- Article
P3‐273: NEUROCHEMICAL AND ELECTROPHYSIOLOGICAL CHARACTERIZATION OF SUVN‐I6107, A NOVEL MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1182, doi. 10.1016/j.jalz.2018.06.1633
- By:
- Publication type:
- Article
P3‐044: SUVN‐502, A PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST, ATTENUATES THE MEMORY DEFICIT CAUSED BY BILATERAL COMMON CAROTID ARTERY LIGATION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1080, doi. 10.1016/j.jalz.2018.06.1399
- By:
- Publication type:
- Article
P2‐234: CORRELATION OF NEUROTRANSMITTER MODULATIONS AND NEURONAL OSCILLATIONS IN RAT BRAIN.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P760, doi. 10.1016/j.jalz.2018.06.921
- By:
- Publication type:
- Article
P2‐080: SUVN‐502: A PURE 5‐HT<sub>6</sub> ANTAGONIST AMELIORATES MEMORY DEFICIT IN TWO DIFFERENTIALLY CHALLENGED SOCIAL RECOGNITION TASKS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P698, doi. 10.1016/j.jalz.2018.06.765
- By:
- Publication type:
- Article
P2‐081: CHARACTERIZATION OF COGNITIVE DISRUPTING PROPERTIES OF PHENYTOIN IN ADULT AND AGED RATS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P699, doi. 10.1016/j.jalz.2018.06.766
- By:
- Publication type:
- Article
P2‐094: SUVN‐502: A PURE 5‐HT<sub>6</sub> RECEPTOR ANTAGONIST ALLEVIATES POST‐MENOPAUSE ASSOCIATED DEMENTIA IN AGED MENOPAUSE WISTAR RATS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P703, doi. 10.1016/j.jalz.2018.06.779
- By:
- Publication type:
- Article
P1‐075: IN‐VIVO CHARACTERIZATION OF SUVN‐I2004: AN M<sub>1</sub> POSITIVE ALLOSTERIC MODULATOR (PAM) IN ANIMAL MODELS OF COGNITION AND SAFETY.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P299, doi. 10.1016/j.jalz.2018.06.077
- By:
- Publication type:
- Article
P1‐077: IN‐VITRO CHARACTERIZATION OF SUVN‐I2004: A NOVEL MUSCARINIC M<sub>1</sub> POSITIVE ALLOSTERIC MODULATOR.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P300, doi. 10.1016/j.jalz.2018.06.079
- By:
- Publication type:
- Article
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
- Published in:
- Clinical Drug Investigation, 2018, v. 38, n. 5, p. 401, doi. 10.1007/s40261-018-0618-4
- By:
- Publication type:
- Article
SUVN-G3031, A SELECTIVE H3 RECEPTOR INVERSE AGONIST: ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P261, doi. 10.1016/j.jalz.2017.06.130
- By:
- Publication type:
- Article
SUVN-I6107: A NOVEL MUSCARINIC M1 RECEPTOR-POSITIVE ALLOSTERIC MODULATOR (M1-PAM) DEVOID OF CHOLINERGIC SIDE EFFECTS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P268, doi. 10.1016/j.jalz.2017.06.146
- By:
- Publication type:
- Article
SUVN-502 (5-HT6 ANTAGONIST) POTENTIATES THE EFFECTS OF MEMANTINE IN ANIMAL MODELS OF COGNITION.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P277, doi. 10.1016/j.jalz.2017.06.165
- By:
- Publication type:
- Article
NOVEL OBJECT RECOGNITION TASK: A SENSITIVE AND RELEVANT ANIMAL MODEL SYSTEM FOR EVALUATING POSTMENOPAUSE-RELATED DEMENTIA.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P287, doi. 10.1016/j.jalz.2017.06.187
- By:
- Publication type:
- Article